Could there be a drug that can both treat and protect against COVID-19? The answer may be found in antibody drugs, a promising therapeutic modality against the coronavirus.
A new test manufactured by A*STAR’s Diagnostics Development Hub in partnership with Duke-NUS Medical School could reveal if an individual is likely immune to COVID-19.
Sebastian Maurer-Stroh shares how bioinformatics has enabled Singapore to respond quickly to COVID-19 and will continue to play an important role in ongoing surveillance.
Scientists at A*STAR have found that a mutation in SARS-CoV-2 called ∆382 leads to milder clinical outcomes, with implications for COVID-19 treatments and vaccines.
Regular disinfection can help to limit the spread of viral infections such as COVID-19, but only if carried out appropriately, write Xian Jun Loh and colleagues.
Uttam Surana shares how SiNOPSEE Therapeutics, the biopharmaceutical startup he co-founded, is developing drugs to block angiogenesis in cancer and degenerative eye conditions.
In a display of scientific willpower, A*STAR researchers developed and deployed the COVID-19 diagnostic Fortitude Kit within weeks of the virus reaching Singapore’s shores.
Curiox Biosystems, an A*STAR spin-off company, specializes in automated and quantitative cell analysis. Its CEO, Namyong Kim, shares the story of the company’s success.
After a decade of research and innovation, homegrown biotech company MiRXES can now call themselves a global leader in developing microRNA-based technology to solve real-world issues.
Lisa F. P. Ng, a leading infectious disease expert on infection and immunity, shares how her team’s prior experience has helped them quickly understand the nature of SARS-CoV-2, the virus that causes COVID-19.
Page
Get the PDF delivered to your inbox.
By entering your email, you also agree to be added to the A*STAR Research mailing list.
Get the PDF delivered to your inbox.
By entering your email, you also agree to be added to the A*STAR Research mailing list.
Join our mailing list
Stay up to date with the latest research highlights from A*Star.